Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma-Reference-Cited by-同舟云学术

Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma

Published:2021-06-11 Issue: Volume:2021 Page:1-4
ISSN:2090-651X
Container-title:Case Reports in Endocrinology
language:en
Short-container-title:Case Reports in Endocrinology

Author:

Murayama Daisuke¹^ORCID,Toda Soji¹^ORCID,Okubo Yoichiro²^ORCID,Hayashi Hiroyuki³,Matsui Ai¹,Yasukawa Mio¹,Iwasaki Hiroyuki¹^ORCID

Affiliation:

1. Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan

2. Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan

3. Department of Pathology, Yokohama Municipal Citizen’s Hospital, 1-1 Mitsuzawanishicho Kanagawa-ku, Yokohama, Kanagawa 221-0855, Japan

Abstract

Thyroid-associated ophthalmopathy (TAO) is an inflammation of the extraocular muscles and periorbital connective tissue caused by autoantibodies against common antigens to both the thyroid and orbit. The release of antigens and induction of hypothyroidism caused by radioactive iodine (RAI) therapy may exacerbate TAO. Here, we present the case of a 67-year-old-woman treated with RAI therapy for metastatic follicular thyroid carcinoma who presented with TAO during the course of sorafenib administration. Tg and TgAb levels were gradually decreased with sorafenib and lenvatinib treatment, and TAO was improved without any ophthalmologic treatment.

Publisher

Hindawi Limited

Subject

Endocrinology, Diabetes and Metabolism

Link

http://downloads.hindawi.com/journals/crie/2021/3024639.pdf

Reference13 articles.

1. TSH-R expression and cytokine profile in orbital tissue of activevs.inactive Graves’ ophthalmopathy patients

2. Thyroid-Associated Ophthalmopathy after Treatment for Graves’ Hyperthyroidism with Antithyroid Drugs or Iodine-131

3. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

4. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

5. Thyroid eye disease associated with athyria

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Graves’ orbitopathy development in thyroid cancer patients: a 16-year nationwide cohort study in South Korea;Eye;2024-06-28

2. Graves’ orbitopathy development in thyroid cancer patients: A 16-year nationwide cohort study in South Korea;2023-09-22

3. Histological findings of thyroid cancer after lenvatinib therapy;Histopathology;2023-07-28